MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ejh.13023

Медицинская библиотека · European journal of haematology · 2018

Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.

Geelen Inge G P, Thielen Noortje, Janssen Jeroen J W M, Hoogendoorn Mels, Roosma Tanja J A, Valk Peter J M, Visser Otto, Cornelissen Jan J, Westerweel Peter E

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

The monitoring of response in chronic myeloid leukemia (CML) is of great importance to identify patients failing their treatment in order to adjust TKI choice and thereby prevent progression to advanced stage disease. Cytogenetic monitoring has a lower sensitivity, is expensive, and requires invasive bone marrow sampling. Nevertheless, chronic myeloid leukemia guidelines continue to recommend performing routine cytogenetic response assessments, even when adequate molecular diagnostics are available.

METHODS

In a population-based registry of newly diagnosed CML patients in the Netherlands, all simultaneous cytogenetic and molecular assessments performed at 3, 6, and 12 months were identified and response of these matched assessments was classified according to European Leukemia Net (ELN) recommendations. The impact of discrepant cytogenetic and molecular response classifications and course of patients with additional chromosomal abnormalities were evaluated.

RESULTS

The overall agreement of 200 matched assessments was 78%. In case of discordant responses, response at 24 months was consistently better predicted by the molecular outcome. Cytogenetic response assessments provided relevant additional clinical information only in some cases of molecular "warning." The development of additional cytogenetic abnormalities was always accompanied with molecular failure.

CONCLUSION

We conclude that it is safe to omit routine cytogenetics for response assessment during treatment and to only use molecular monitoring, in order to prevent ambiguous classifications, reduce costs, and reduce the need for invasive bone marrow sampling. Cytogenetic re-assessment should still be performed when molecular response is suboptimal.

Для цитирования: Geelen Inge G P, Thielen Noortje, Janssen Jeroen J W M, Hoogendoorn Mels, Roosma Tanja J A, Valk Peter J M, Visser Otto, Cornelissen Jan J, Westerweel Peter E. Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.. European journal of haematology. 2018. DOI: 10.1111/ejh.13023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.